Quality: Good

pxa

PXA: Digital Settlement Monopoly - Regulatory Reckoning Looms

Updated 6 Nov 2025

Fair value $6.00 vs current $15.53 (-61%). Australian monopoly faces IPART repricing (2H26), interoperability risk (40% probability 2nd operator FY27-28), and UK execution binary (viability threshold 2+ lenders by FY26).

View note
nab

NAB: Big 4 Banking - Overvalued at the Peak

Updated 6 Nov 2025

Fair value $25.50 vs current $43.67 (-41.6%). Mature banking franchise at cost of equity equilibrium offering 7.2% yield (10-11% franked) with limited capital appreciation. ROE 11.4% declining to 10.5% terminal as competitive intensity constrains returns.

View note
sdf

SDF: Insurance Broker Aggregator - Premium Cycle's Bottoming, Network's Compounding

Updated 6 Nov 2025

Australia's #1 insurance broker aggregator (16% share, 402 members) trades 8% below $6.56 fair value despite fortress financials (18.7% ROIC, 127% FCF conversion). Premium cycle trough (1-2% pricing) normalises FY27-28 driving $125m revenue per 1% uplift.

View note
RMD

RMD: Sleep Health Pioneer - Margin Peak Before the Mean Reversion

Updated 3 Nov 2025

Healthcare technology leader with 28.5% market share and 94.3% device connectivity. Fair value $187.65 vs current $128 (47% upside). EBITDA margins peak 37.5% FY26 before compression to 30.7% terminal. Medicare risk 85% probability. Quality score 7.6/10.

View note
WBC

WBC: Banking Giant - Transformation Troubles, Trough Credit Masking Reality

Updated 3 Nov 2025

Westpac trades 40% above $23.71 fair value despite operational deterioration. Cost-to-income rising to 53% (vs CBA's 43%) whilst UNITE delivers zero efficiency gains. Credit at unsustainable 5bps trough. Expected returns -11.2% annually. Avoid.

View note
CGF

CGF: Retirement Income Leader - Peak Margins, Fading Moat

Updated 31 Oct 2025

AVOID. Fair value $8.38 vs current $9.16 (-9% downside). Challenger dominates 60% annuity share with 67.7% EBITDA margins, but faces compression to 58% as banks enter FY27. ROIC 12.5% declining to 10.0% vs 14.0% WACC. Quality 7.33/10, wide moat narrowing 6-8 years.

View note
CSL

CSL: Plasma Giant - Transformation or Overvaluation?

Updated 29 Oct 2025

CSL trades at $220.29 vs fair value $136.28 (62% premium). Strong plasma oligopoly moat (7.7/10 quality) executing $500M transformation targeting 34% EBITDA margins by FY28. Revenue growth 5.6% CAGR, but current valuation appears to fully reflect optimistic scenarios with limited margin of safety.

View note
wzr

WZR: Fintech Lending Platform - Operational Excellence, Capital Structure Mess

Updated 28 Oct 2025

Technology-driven consumer lending platform with superior credit quality (807 vs peer 650-780) but faces fundamental capital structure challenges. Fair value $0.25 vs current $3.50 implies -93% return. Negative FCF requires perpetual dilution.

View note
hgh

HGH: Specialist Banking Transformation - Demographic Goldmine at Cyclical Trough

Updated 24 Oct 2025

Heartland Group Holdings: Fair value $2.24 vs current $0.955 (+136% upside). Specialist banking transformation with reverse mortgage dominance, ADI deposit advantages, demographic tailwinds. Credit cycle recovery catalyst.

View note
ccr

CCR: Debt Collections Disruptor - AI-Powered Turnaround Trades at Steep Discount

Updated 24 Oct 2025

Credit Clear trades at $0.27 vs fair value $0.45 (67% upside), recently profitable with 15.8% EBITDA margin, 95% Tier-1 retention, technology moat 5-7 years

View note
syl

SYL: Infrastructure Contractor - Victorian Peak Meets Utility Pivot

Updated 24 Oct 2025

Fair value $2.65 with 18.6% ROIC premium to sector. Victorian concentration risk offset by utility acquisitions and renewables positioning.

View note
asx

ASX: Exchange Operator - Monopoly Under Scrutiny, Margin Recovery Ahead

Updated 24 Oct 2025

ASX trades at $58.42 vs fair value $70.15 (+20% upside). Dominant market position with 61% EBITDA margins, 13.8% ROIC. Near-term regulatory and execution risks offset by structural moat and superannuation tailwinds.

View note